Evolution Devices

Evolution Devices operates at the intersection of medical devices, rehabilitation technology, digital health, and wearables. Its primary differentiation is the combination of a wearable functional electrical stimulation device with adaptive control software: EvoWalk is designed to support ankle dorsiflexion and assist knee flexion or extension, while its stimulation timing is intended to adapt across users, walking speeds, terrains, gaits, and activities. The company also has a research-oriented product in EvoVision, a markerless motion-capture platform that uses multiple web cameras to generate gait and biomechanical data without physical markers or sensors. This gives Evolution Devices a broader offering than a single assistive orthotic, spanning intervention and measurement. The FDA 510(k) clearance recorded in January 2024 is an important regulatory differentiator, although the available profile does not provide comparative clinical, commercial, or market-share data. With approximately $1.63 million in total recorded funding and an employee range of 11–50, the company appears to remain an early-stage specialist rather than a scaled category incumbent.

Evolution Devices shows a progression from university-linked early development to regulated medical-device commercialization. The company was founded on Jul 18, 2017, followed by a Mar 10, 2019 pre-seed round and a second pre-seed round dated Sep 17, 2020. Early ecosystem support included SkyDeck Berkeley and Cibersons, while Alchemist Accelerator is associated with the 2020 financing. The company then added a $244,990 grant on Jul 7, 2020, a $241,070 equity-crowdfunding round on Jan 1, 2022, and a $998,608 grant on Jun 1, 2022. A further $149,548 crowdfunding round on Sep 12, 2023 brought recorded funding to $1,634,216 across six rounds. The major operating inflection point was EvoWalk’s FDA 510(k) clearance announced in January 2024, moving the flagship product beyond development into a regulated commercial category. EvoVision extends the platform toward gait research and measurement. However, public evidence of post-clearance revenue growth, hiring expansion, additional product launches, or new financing after September 2023 is limited.